DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced that it has raised $5.0 million in a three-year debt financing arrangement with Silicon Valley Bank and Oxford Finance Corporation. The financing will be used primarily to fund the Company’s three ongoing clinical trials in renal cell carcinoma (Phase 2), chronic lymphocytic leukemia (Phase 1/2) and HIV (Phase 1), utilizing its personalized RNA-loaded dendritic cell-based immunotherapy (“Arcelis”) technology for cancer and HIV.
